Freeport, Bahamas, The, June 09, 2012 --(PR.com
)-- Okyanos Heart Institute (http://www.okyanos.com/), which brings a new standard of care and a better quality of life to patients with “no-option” coronary artery disease (CAD) via cardiac adult stem cell therapy, has announced that Matt Feshbach, CEO and co-founder, recently presented at the 2012 Global Connected Care Conference and 3rd MediTour Expo in Las Vegas. Speaking in a presentation titled, “The Okyanos Story: Building a Global Care Facility with Stem Cell Research,” Feshbach presented to global healthcare professionals at the two-day international conference, which brought together world healthcare leaders to discuss the latest trends and opportunities in healthcare and the medical tourism industry.
Prior to the establishment of Okyanos Heart Institute, Feshbach worked for more than 30 years as an investor. Extensive research led Feshbach to believe that stem cell therapy could provide an answer to the largest unmet healthcare need in the Western world: heart disease. Along with Manuel Vianna, Feshbach established Okyanos Heart Institute in an effort to provide cardiac adult stem cell therapy to people with CAD who have exhausted all available options from the current standard of care.
“Okyanos Heart Institute is bringing a new option to the biggest unmet need in healthcare, cardiovascular disease and in particular to those patients with no-option coronary artery disease,” said Feshbach. “I thank the Global Connected Care and 3rd Meditour Expo for including Okyanos in the discussion on improving the quality and total cost of care to patients.”
New Media Content:
Okyanos LinkedIn page:
Okyanos Facebook page:
Okyanos Twitter page:
About Okyanos Heart Institute:
Based in Freeport, The Bahamas, the Okyanos Heart Institute is a Center of Excellence (CoE) adhering to U.S. surgical center standards and led by Chief Medical Officer Howard Walpole Jr., M.D., MBA, FACC, FACAI, FSCAI, a leader of the American College of Cardiology for many years. The mission of Okyanos Heart Institute is to bring a new standard of care and a better quality of life to patients with “no-option” coronary artery disease via cardiac adult stem cell therapy. The Greek god of rivers, “Okyanos” symbolizes the primary mechanism of action that these adult stem cells have on ischemic (lack of blood flow) heart tissue, the result of the plaque deposits in the coronary arteries. The stem cells, derived from a person’s adipose (fat) tissue, create new blood vessels, a process known as angiogenesis. These cells facilitate blood flow in the heart and intake and use of oxygen, as measured by a rigorous clinical trial known as the PRECISE trial, as well as cardiac cell therapy trials at leading research institutions. For more information, visit http://www.okyanos.com/.
MMI Public Relations